Cardiac Repolarization
Conditions
Brief summary
This will be a Phase 1, single-center, 2-part study in healthy subjects. Parts 1 and 2 need to be conducted in sequential order.
Detailed description
Part 1 will enroll up to 3 cohorts of 6 healthy adult subjects to receive a single dose. The total duration of participation from the Screening visit to the follow-up will be up to 7 weeks (up to 45 days). Part 2 of this study will randomize approximately 32 subjects. The total duration of participation from the Screening visit to the follow-up will be up to 8 weeks (up to 55 days).
Interventions
DRUGPlacebo
Participants will receive a single dose of placebo on Day 1, Day 8 or Day 15 of part 2
DRUGMoxifloxacin (positive control)
Participants will receive a single dose of moxifloxacin on Day 1,Day 8, or Day 15 of Part 2
DRUGMilademetan
Participants will receive a single dose of Milademetan on Day 1 for part 1 Participants will receive a single dose of milademetan on Day 1, Day 8, or Day 15 of Part 2
Sponsors
Rain Oncology Inc
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Is capable of understanding informed consent and is willing and able to provide written informed consent. 2. Is willing to comply with all protocol procedures. 3. Healthy, male, nonsmoking (for at least 90 days) subjects from 18 through 55 years of age, inclusive, at Screening, and healthy, female, nonsmoking (for at least 90 days) subjects of nonchildbearing potential from 18 through 55 years of age, inclusive, at Screening. 4. Body weight \> 50 kg, body mass index between 18.0 and 30 kg/m2, inclusive.
Exclusion criteria
1. Past or present clinically relevant systemic disease as judged by the Investigator including, but not limited to, clinically relevant medical abnormalities such as psychiatric, neurologic, pulmonary, respiratory, cardiac, gastrointestinal, genitourinary, renal, hepatic, metabolic, endocrinologic, hematological, or autoimmune disorders making implementation of the protocol or interpretation of the study results difficult, or that would put the subject at risk by participating in the study in the opinion of the Investigator. 2. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee). 3. Knowledge of any kind of cardiovascular disorder/condition/procedure known to increase the possibility of QT prolongation or a history of additional risk factors for torsade de pointes (eg, heart failure, hypokalemia, hypomagnesemia, congenital long QT syndrome, or family history of long QT syndrome, or Brugada syndrome), or cardiac conduction disorders. 4. Resting supine systolic blood pressure greater than 140 mm Hg; resting supine diastolic blood pressure greater than 90 mm Hg at Screening or Day -1. Blood pressure measurements may be repeated once at the discretion of the Investigator. 5. Resting supine HR less than 45 beats per minute or greater than 100 beats per minute at Screening or Day -1 (may be repeated once at the discretion of the Investigator). Minor deviations are acceptable if considered to be of no clinical significance by the Investigator. 6. Abnormal 12-lead ECG at Screening or Day -1 (a single repeat is allowed), including: 1. QTcF \> 450 msec 2. QRS \> 110 msec 3. PR \> 200 msec 4. Second or third-degree atrioventricular block 7. Any rhythm other than sinus rhythm, which is interpreted by the Investigator to be clinically significant at Screening or Day -1. 8. Dosing in another clinical trial within the last 30 days (or 5 half-lives, whichever is longer) prior to Day -1. 9. Family history of unexplainable sudden death at \< 50 years of age. 10. History of unexplained loss of consciousness, unexplained syncope, unexplained irregular heartbeats or palpitations, clinically significant head injury, or near drowning with hospital admission. 11. Known allergic reactions to moxifloxacin (for Part 2 only) or any study medication or history of tendonitis or tendon rupture as a result of moxifloxacin or any other quinolone type drug use (for Part 2 only).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with adverse events (AEs) | Part 1:Up to 15 days | The intensity of all AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
| Incidence of laboratory abnormalities based on hematology test results | Part 1:Up to 15 days | Hematocrit, Hemoglobin, Mean cell hemoglobin |
| Incidence of laboratory abnormalities based on clinical chemistry test results | Part 1:Up to 15 days | Alanine aminotransferase, Albumin, Alkaline phosphatase, Aspartate aminotransferase |
| Incidence of laboratory abnormalities based on urinalysis test results | Part 1:Up to 15 days | Bilirubin, color and appearance, glucose, ketones, protein |
| Vital signs measurements | Part 1:Up to 15 days | Supine systolic blood pressure in mmHg and supine diastolic blood pressure in mmHg |
| Change from baseline in QT interval of the ECG | Part 1:Up to 15 days | QT interval measured in msec |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Observed maximum plasma concentration (Cmax) | Part 1:Up to 15 days | observed maximum plasma concentration in ng/ml |
| Time to observed maximum concentration (Tmax) | Part 1:Up to 15 days | time to observed maximum concentration in hour |
| area under the time-concentration curve from time zero to the time of the last quantifiable concentration (AUC0-tlast) | Part 1:Up to 15 days | Expressed as ng/ml x hr |
Countries
Australia
Outcome results
None listed